Contact Us

Discovery Starts with Me: Audrey Greenberg

September 30, 2021

Center for Breakthrough Medicines is Hiring

CBM is hiring to accelerate the development and manufacturing of advanced therapies

We recently spoke with Audrey Greenberg, co-founder and chief business officer at the Center for Breakthrough Medicines, to learn how her participation in the Collaborative is supporting her organization’s mission of saving lives by refining and accelerating the development and manufacturing of advanced therapies, and to record her story for the CEO Council’s “Discovery Starts with Me” video series.

“We are hiring at every level of the organization,” Greenberg said. The Center for Breakthrough Medicines, which currently employs 80+ people, plans to onboard 50-100 more hires by the end of 2021, and then 500 new staff members each year for the subsequent four years, growing the company to 2,000 employees by 2024 at the King of Prussia site. “The advanced therapy revolution will require an ever-increasing number of trained professionals. We participate in programs to retrain displaced workers for the industry, and we promote in schools the life science industry as a great career path here in Philadelphia,” she added.

Ready full story

Center for Breakthrough Medicines Appoints Peter Carbone as COO

Increased Leadership Hires Signal Strong Growth for CBM

KING OF PRUSSIA, Pa., Sept. 29, 2021 — The Center for Breakthrough Medicines (CBM) announced today the appointment of Peter Carbone to Chief Operating Officer (COO). CBM is creating the world’s largest end-to-end advanced therapy contract development and manufacturing organization (CDMO). CBM will provide pre-clinical through commercial manufacturing including process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities .

Peter has over 30 years of Operations, Quality, and Technology leadership experience focused on building out or advancing global capabilities within small to large pharmaceutical companies. Peter is an accomplished Operations and Quality Executive who has served in multi-billion-dollar companies operating in biotech, pharmaceutical, and medical device markets.

“Peter brings CBM a myriad of valuable skills sets,” said Audrey Greenberg, Co-Founder, Center for Breakthrough Medicines. “In addition to his incredible work in big pharma, Peter also possesses specific experience starting and building a CDMO for Akzo Nobel. His background and dedication to bringing life-saving therapies to patients makes him a great asset for CBM and the greater life science community.”

Carbone is a seasoned life science veteran with extensive experience building global teams designed to bring advanced therapies to patients. Most recently Peter served as Executive Vice President, Quality at Accorda Therapeutics. In this position, Peter successfully worked on the commercialization of the drug-device combination Inbrija (levodopa inhalation powder) for Parkinson’s disease.

“We are very lucky to include a life science executive of Peter’s caliber to our team,” said Joerg Ahlgrimm, CEO, CBM. “Peter has my full confidence and support as he pursues his passion for bringing life-saving medicines to patients. Peter’s addition to the team comes on the heels of other additions to CBM’s key leadership and management teams. With these top-echelon leaders CBM is on track to become the number one CDMO focused on cell and gene therapy.”

Carbone focuses on the strategic buildout of agile, best in class operations, systems, and organizations. Over his 30-year career, Carbone held positions of increasing responsibility at Novartis, Bayer and Amgen. At Novartis, Peter was head of Americas and special technologies, a role the required extended periods of service at the Novartis headquarters in Basel, CH. And, after his service for Bayer Biologics, Peter successfully navigated Akzo Nobel through the transition of its CRO business into a CDMO model. Over his career, Peter has a demonstrated ability to foster and create a corporate culture that excels at science and operations. In the teams he builds he utilizes knowledge management, risk management, and science as well as data-driven decision making as pillars for leadership excellence.

“I am excited to be a part of CBM and its mission. We are not here to make products for our customers, we are here to make our customers’ products a reality,” said Peter Carbone. “We are a true scientific and full life cycle partner, and we will deliver a very mature and robust platform for quality management systems and regulatory science for small and large cell and gene therapy innovators. Ultimately, my passion is for our primary customer – the patients and their loved ones.”

CBM Increases Leadership Ranks
In line with CBM’s mission to build the biggest and best cell and gene CDMO here in Cellicon Valley, it is hiring the best and brightest leaders. In addition to the recent promotion of Joerg Ahlgrimm from COO to CEO, and his replacement with Carbone, CBM has made numerous strategic hires.

The Center for Breakthrough Medicines
The Center for Breakthrough Medicines (CBM) is the most comprehensive advanced therapy CDMO partner in the industry servicing pre-clinical to commercial phase therapies, following a molecule from idea to launch and providing a full spectrum of services all in one location. This horizontal integration enables the utmost quality and accelerates time to market with single-source, end-to-end solutions.

###

Media Contact:
John F. Kouten, DeFazio Communications
(o) 609-241-7352 (c) 908-227-4714
John@defaziocommunications.com

September 29, 2021

Center for Breakthrough Medicines Appoints Joerg Ahlgrimm as CEO

KING OF PRUSSIA, Pa., Sept. 23, 2021 /PRNewswire/ — The Center for Breakthrough Medicines (CBM) announced today the appointment of Joerg Ahlgrimm to Chief Executive Officer. CBM is creating the world’s largest end-to-end advanced therapy contract development and manufacturing organization (CDMO). CBM will provide pre-clinical through commercial manufacturing including process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities.

Ahlgrimm brings over 20 years of expertise in the areas of operations and supply chain management and has served in multi-billion-dollar companies operating in biotech, vaccines, pharmaceutical and medical device markets. His focus is on superior customer service, strategy development, execution management, productivity improvement, organizational development, team building, and leadership.

Prior to joining CBM, Ahlgrimm was Head of Global Operations Pharma Biotech and Nutrition at Lonza, where he was responsible for 37 sites on four continents and over 8,000 employees. Before Lonza, Ahlgrimm was Head of Global Manufacturing for Baxter Healthcare’s BioScience Division, Baxalta Inc. In this senior leadership role, he led Baxalta’s internal and external manufacturing network and created an impressive track record in customer service, growth and operational efficiency.

“We are thrilled about Joerg’s appointment to CEO. Joerg’s ‘team player’ mentality, ability to roll up his sleeves, and deep industry relationships will be a game changer for CBM and the advanced therapies industry. Joerg has a proven ability to execute on large-scale projects,” said Audrey Greenberg, Co-Founder, Center for Breakthrough Medicines. “Joerg’s extraordinary achievements for the pharma, biotech, and CDMO industries combined with his incredible leadership, makes him the ideal choice to head our executive management team and build CBM into an advanced therapy powerhouse.”

Mr. Ahlgrimm joined CBM in September 2020 as Chief Operating Officer. His invaluable contribution to launching and establishing CBM distinguishes Joerg as the ideal choice for the role of CEO. In this new position, Joerg will increase his responsibilities and focus on driving the growth of CBM.

“I am laser-focused on building a company that will solve the biggest challenge in cell and gene therapy development, which is manufacturing,” said Joerg Ahlgrimm. “Beyond manufacturing, our goals include the creation of high-performing teams and fostering an exciting and inspiring culture with a close connection to the patients and customers we ultimately serve.”

“Situated in the heart of Cellicon Valley, the Center for Breakthrough Medicines is in the global epicenter of the cell and gene therapy industry,” said Brian O’Neill, Founder and Executive Chairman, The Center for Breakthrough Medicines. “Thanks to the efforts of Joerg, and the entire team he has assembled and continues to build, we are better positioned to win. I look forward to working with Joerg as he continues to build CBM into an industry-leading CDMO that benefits patients, employees, customers, and the communities in which we operate.”

The Center for Breakthrough Medicines
The Center for Breakthrough Medicines (CBM) is the most comprehensive advanced therapy CDMO partner in the industry servicing pre-clinical to commercial phase therapies, following a molecule from idea to launch and providing a full spectrum of services all in one location. This horizontal integration enables the utmost quality and accelerates time to market with single-source, end-to-end solutions.

Media Contact:
John F. Kouten, DeFazio Communications
(o) 609-241-7352 (c) 908-227-4714
John@defaziocommunications.com

September 23, 2021

Webinar: Proven Quality – Preventing quality issues during drug development

Center For Breakthrough Medicines VP, Quality and Regulatory Mike McCormick and Sr. Director, Vector Engineering & Manufacturability Brian Tomkowicz were recently featured on the Fierce Biotech webinar, “Proven Quality – Preventing quality issues during drug development.” Both provided valuable insight on a wide range of quality control, including how drug developers can prepare and collaborate with CDMOs to meet the FDA’s standards and avoid any manufacturing issues. Thanks to host Noah Higgins-Dunn at FiercePharma and Jillian Blauvelt at Questex for providing the platform for this important discussion.

View the archived presentation

September 20, 2021

Audrey Greenberg Joins Money Matters TV Show #21-37

September 10, 2021

The Future of Cell and Gene Therapy with Bruce Levine and Audrey Greenberg

CBM founder Audrey Greenberg talks about The Future of Cell and Gene Therapy

September 7, 2021